A small nonprofit group that assesses the value of medicines — and proposes a fair price — is quickly gaining value itself.
For the past two years, the Institute for Clinical and Economic Review has issued high-profile reports assessing the worth of pricey new drugs for treating hepatitis C and high cholesterol, among other conditions. It argued last fall, for instance, that a pair of new cholesterol drugs would be more cost-effective at about $2,100, not $14,100, a year.
Read Full Article »